GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Novartis AG ADR NVS · USD

Health Care · US listing · 🇺🇸 United States

Compare

163.69

+0.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$54.81bn

FY2016FY2025

Net income

$14.06bn

FY2016FY2025

Free cash flow

$17.69bn

FY2016FY2025

Shareholders' equity

$46.13bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$54.81bn$51.72bn$46.66bn$43.46bn$43.97bn$49.90bn$48.68bn$46.10bn$43.40bn$49.44bn
Gross profit$41.12bn$38.90bn$34.19bn$31.88bn$32.24bn$34.78bn$34.25bn$31.59bn$29.77bn$31.92bn
Research and development$10.74bn$10.02bn$11.37bn$9.17bn$8.64bn$8.98bn$9.40bn$8.49bn$8.39bn$9.04bn
Operating income$17.07bn$14.54bn$9.77bn$7.95bn$10.95bn$10.75bn$9.09bn$8.40bn$9.39bn$8.27bn
Net income$14.06bn$11.94bn$14.85bn$6.96bn$24.02bn$8.07bn$11.73bn$12.61bn$7.70bn$6.71bn
Diluted earnings per share7.295.967.193.2310.663.545.125.403.282.80

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$115.57bn$102.25bn$99.94bn$117.45bn$131.79bn$132.19bn$118.41bn$145.56bn$133.08bn$130.12bn
Cash and short-term investments$11.59bn$13.35bn$13.96bn$18.61bn$28.11bn$11.56bn$11.45bn$15.96bn$9.48bn$7.78bn
Total liabilities$69.02bn$58.12bn$53.20bn$58.03bn$63.97bn$75.52bn$62.86bn$66.87bn$58.85bn$55.23bn
Debt$35.38bn$31.26bn$26.35bn$27.91bn$31.02bn$37.85bn$29.15bn$32.09bn$28.43bn$25.95bn
Shareholders' equity$46.13bn$44.05bn$46.67bn$59.34bn$67.66bn$56.60bn$55.47bn$78.61bn$74.17bn$74.83bn
Shares outstanding1,929m2,004m2,065m2,150m2,253m2,282m2,292m2,336m2,348m2,395m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$19.24bn$17.62bn$14.46bn$14.24bn$15.07bn$13.65bn$13.63bn$14.27bn$12.62bn$11.47bn
Capital spending−$1.56bn−$3.81bn−$2.75bn−$2.67bn−$2.97bn−$2.58bn−$2.26bn−$3.35bn−$2.75bn−$2.88bn
Free cash flow$17.69bn$13.80bn$11.71bn$11.56bn$12.10bn$11.06bn$11.37bn$10.92bn$9.88bn$8.60bn
Dividends paid−$7.86bn−$7.62bn−$7.25bn−$7.51bn−$7.37bn−$6.99bn−$6.64bn−$6.97bn−$6.50bn−$6.47bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$14.42bn$13.52bn$13.33bn$14.36bn$14.84bn$13.62bn$13.56bn$13.17bn
Gross profit$10.74bn$10.06bn$9.79bn$10.82bn$11.51bn$10.39bn$10.23bn$9.94bn
Operating income$4.74bn$4.24bn$3.52bn$4.50bn$4.86bn$4.66bn$3.53bn$3.63bn
Net income$3.27bn$3.16bn$2.41bn$3.93bn$4.04bn$3.61bn$2.82bn$3.19bn
Diluted earnings per share1.711.651.252.042.091.871.411.59
Cash from operations$5.89bn$3.68bn$2.25bn$6.57bn$6.66bn$3.65bn$4.19bn$6.29bn
Capital spending−$321.0m−$807.0m−$610.0m−$831.0m−$558.0m−$1.49bn−$1.13bn−$799.0m
Free cash flow$5.57bn$2.87bn$1.64bn$5.74bn$6.11bn$2.15bn$3.06bn$5.49bn
Total assets$122.03bn$118.53bn$115.57bn$107.29bn$104.39bn$99.94bn$102.25bn$103.52bn
Cash and short-term investments$7.69bn$6.98bn$11.59bn$9.75bn$7.00bn$7.20bn$13.35bn$14.02bn
Debt$47.35bn$45.34bn$35.38bn$32.02bn$32.64bn$31.27bn$31.26bn$30.56bn
Shareholders' equity$41.54bn$38.51bn$46.13bn$44.33bn$41.98bn$38.37bn$44.05bn$43.32bn

Financial ratios

Data as of 3 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin75.0%75.2%73.3%73.4%73.3%69.7%
Operating margin31.2%28.1%20.9%18.3%24.9%21.5%
Net margin25.6%23.1%31.8%16.0%54.6%16.2%
Return on equity30.5%27.1%31.8%11.7%35.5%14.3%
Return on assets12.2%11.7%14.9%5.9%18.2%6.1%
Free cash flow yield6.6%6.6%5.1%4.8%4.9%4.4%
Revenue growth6.0%10.8%7.4%-1.2%-11.9%2.5%
Earnings growth17.7%-19.6%113.5%-71.0%197.6%-31.2%
Current ratio1.12x1.04x1.16x1.29x1.51x0.90x
Debt to equity0.73x0.67x0.53x0.44x0.43x0.64x
Equity ratio39.9%43.1%46.7%50.5%51.3%42.8%
Interest coverage14.38x14.03x11.15x9.52x12.10x11.67x
R&D as a share of sales19.6%19.4%24.4%21.1%19.7%18.0%
Buybacks as a share of market value3.7%3.0%4.0%4.6%1.3%0.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.0%1.9%0.8%
Operating income29.0%9.7%6.6%
Net income26.4%11.7%-2.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.1%74.3%73.3%70.7%
Operating margin29.7%25.1%24.4%21.8%
Net margin24.4%24.3%27.5%25.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings18.916.314.026.57.825.317.513.521.722.0
Price to sales4.83.84.54.34.24.14.23.73.93.0

Market value over time

31 Oct 2016 to 2 Sept 2026, in USD

$142.67bn$310.95bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return40%-1%15%6%-4%-6%25%1%15%-16%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.